Last ¥1,200 JPY
Change Today +1.00 / 0.08%
Volume 552.1K
4506 On Other Exchanges
Symbol
Exchange
Berlin
Tokyo
OTC US
OTC US
As of 1:00 AM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

sumitomo dainippon pharma co (4506) Snapshot

Open
¥1,199
Previous Close
¥1,199
Day High
¥1,209
Day Low
¥1,199
52 Week High
01/10/14 - ¥1,947
52 Week Low
05/27/14 - ¥1,095
Market Cap
477.5B
Average Volume 10 Days
1.4M
EPS TTM
¥58.20
Shares Outstanding
397.9M
EX-Date
03/27/15
P/E TM
20.6x
Dividend
¥18.00
Dividend Yield
1.50%
Current Stock Chart for SUMITOMO DAINIPPON PHARMA CO (4506)

Related News

No related news articles were found.

sumitomo dainippon pharma co (4506) Related Businessweek News

No Related Businessweek News Found

sumitomo dainippon pharma co (4506) Details

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others in Japan, China, North America, and other regions. The company offers pharmaceutical products, such as therapeutic agents for hypertension, angina pectoris, arrhythmia, Parkinson’s disease, systemic fungal infections, and hepatocellular carcinoma; atypical antipsychotics; antidepressants; rapid-acting insulin secretagogues; vasodilators; and biguanide oral hypoglycemic drugs. It also provides products for therapeutic indications, such as Anderson-Fabry disease, anti-hypertension, gastroprokines, carbapenem antibiotics, sedative hypnotics, short-acting and long-acting beta-agonist, inhaled corticosteroid, corticosteroid nasal spray, and serotonin-agonist antianxiety drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, seasonings, and sweeteners; and chemical product materials, such as cosmetic and coating materials, active pharmaceutical ingredients, and electronic chemicals. Further, it offers veterinary medicines for companion animals, including dogs and cats; and farm animals, such as cattle, swine, horses, and cultured fish. Additionally, the company develops point-of-care testing diagnostic products for infectious diseases and acute myocardial infarctions; in-vitro diagnostics for bone and calcium metabolism, and central nervous system disorders; research materials that facilitate research related to medical care; and BBI608 and BBI503 anticancer drug candidates. It has a joint development agreement with Healios K.K. to develop iPS cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration and other eye diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. The company was founded in 1897 and is headquartered in Osaka, Japan.

7,015 Employees
Last Reported Date: 06/19/14
Founded in 1897

sumitomo dainippon pharma co (4506) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sumitomo dainippon pharma co (4506) Key Developments

Sumitomo Dainippon Pharma Co., Ltd. Announces Executive Changes, Effective from December 1, 2014

Sumitomo Dainippon Pharma Co., Ltd. announced that the following changes in Executive Officers and other key positions will take place as of the respective dates: The Company has announced the change in the post of Hiroshi Nomura Member, Board of Directors, Senior Executive Officer Global Corporate Management; Global Strategy & Business Development; External Affairs; Corporate Secretariat & Industry Affairs; Finance & Accounting; Regenerative & Cellular Medicine Office to Member, Board of Directors, Senior Executive Officer Global Corporate Planning; Global Business Development; External Affairs; Corporate Secretariat & Industry Affairs; Finance & Accounting; Regenerative & Cellular Medicine Office effective December 1, 2014. The company has also announced the change in the position of Hiroyuki Baba from Executive Officer Executive Vice President, Sunovion Pharmaceuticals Inc. to Executive Officer, Executive Vice President, Sunovion Pharmaceuticals Inc.; Director, Global Business Development; Head of Global Business Development for DSP Group effective December 1, 2014. The company announced the change in the position of Hajime Kinuta to Director, Global Corporate Planning from Director, Global Corporate Management; Koichi Kozuki to Director, Global R&D Office from Director, Global Strategy & Business Development, Global R&D Office; Yasushi Matuski to Director, Global Oncology Office to Group Manager, Global Strategy Group, Global Oncology Office and Shigeyuki Nishinaka to Deputy Executive Director, Drug Research Director, External Innovation Development Office to Deputy Executive Director, Drug Research Director, Global Oncology Office, effective from December 1, 2014.

Sumitomo Dainippon Pharma Co., Ltd., Board Meeting, Oct 31, 2014

Sumitomo Dainippon Pharma Co., Ltd., Board Meeting, Oct 31, 2014. Agenda: To consider an idle fixed asset is to be transferred for the purposes of more efficient use of the company's resources and enhancement of the company's financial strength; and to consider the asset to be transferred.

Sumitomo Dainippon Pharma Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2014; Revised Earnings Guidance for the Year Ending March 31, 2015; Announces Interim Dividend for Fiscal 2015; Provides Year End Dividend Guidance for Fiscal 2015

Sumitomo Dainippon Pharma Co., Ltd. reported consolidated earnings results for the six months ended September 30, 2014. For the six months, the company reported operating income of ¥11,945 million, ordinary income of ¥12,712 million and net income of ¥11,758 million or ¥29.60 per basic share on net sales of ¥178,290 million compared to operating income of ¥17,435 million, ordinary income of ¥17,408 million and net income of ¥8,697 million or ¥21.89 per basic share on net sales of ¥181,396 million reported a year ago. Income before income taxes and minority interests was ¥22,054 million compared to ¥14,961 million reported a year ago. Net cash provided by operating activities was ¥21,566 million compared to ¥22,266 million reported a year ago. Purchases of property, plant and equipment was ¥5,016 million compared to ¥7,212 million reported a year ago. Purchases of intangible assets were ¥1,428 million compared to ¥2,505 million reported a year ago. For the year ending March 31, 2015, the company expects to report operating income of ¥20,000 million, ordinary income of ¥19,500 million and net income of ¥14,000 million or ¥35.24 per share on net sales of ¥366,000 million. The forecasted net sales are revised upward by ¥14 billion. The forecasted operating income remains unchanged, because the sales and administration expenses are expected to increase, due mainly to increases in LATUDA sales expenses and in the fee on sales of existing products distributed through the government health care program in North America, which increases are exacerbated by the exchange rate situation when translated into yen. The forecasts for ordinary income and net income of the fiscal year are now both revised upward by ¥0.5 billion and ¥2 billion, respectively, reflecting an improvement in non-operating income and accrual of a larger-than-expected net gain from the sale of fixed assets among the extraordinary income items. The company announced an interim dividend of ¥9.0 per share compared to the same paid a year ago. The company plans to pay year end dividend of ¥9.0 per share compared to the same paid a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4506:JP ¥1,200.00 JPY +1.00

4506 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $15.19 USD +0.05
Eastman Kodak Co $21.00 USD +0.18
FUJIFILM Holdings Corp ¥3,770 JPY +40.50
GlaxoSmithKline Consumer Nigeria PLC 50.00 NGN 0.00
Vanda Pharmaceuticals Inc $14.69 USD +1.11
View Industry Companies
 

Industry Analysis

4506

Industry Average

Valuation 4506 Industry Range
Price/Earnings 18.7x
Price/Sales 1.1x
Price/Book 1.0x
Price/Cash Flow 11.6x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMITOMO DAINIPPON PHARMA CO, please visit www.ds-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.